DF/HCC Pipelines in Oncology: Genelux

Thursday, May 15 at 12:30pm to 2:00pm

DF/HCC is hosting a Pipelines in Oncology Seminar with Genelux Corporation on Thursday, May 15, 2014 from 12:30 - 2:00 pm in Smith 308/309 at the Dana-Farber Cancer Institute. Genelux has developed an oncolytic-virus based technology platform, and a wide variety of payloads that are tools for cancer detection and therapy.  Late phase I studies are promising,  and are being conducted at Royal Marsden Hospital in London, Memorial Sloan Kettering Hospital in New York, UCSD Hospital in San Diego and  University of Leeds Hospital in West Yorkshire, England. They are also working to develop a cancer vaccine.

 

Genelux Founder and CEO Dr. Aladar Szalay will be meeting with investigators at MGH in the morning and DFCI in the afternoon. If you are interested in a small group or 1:1 meeting with Dr. Szalay, please write to Andrea Talis (MGH), or Deborah Goff (DFCI).

 

About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNAs into cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit http://www.genelux.com/

 

Lunch will be provided at DFCI for the seminar. Please register for the seminar at http://events.dfhcc.harvard.edu/events/58

Share
Subscribe
Event Type

Clinical Research

Event Contact Email

deborah_goff@dfci.harvard.edu

Event Contact Phone

617-632-4044

Recent Activity

Event Registration Required

This event requires registration.


NCI CCC